QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
Summary
QIAGEN acquired a 96% majority stake in BLIRT S.A., a Polish manufacturer of recombinant enzymes and molecular biology reagents. The deal expands QIAGEN’s R&D and manufacturing capacity and strengthens its sample technologies business. It also adds geographic reach, new sales channels, and extra supply chain resilience. BLIRT’s capabilities in customized and standardized enzymes make the acquisition strategically important for QIAGEN’s life sciences and diagnostic kits portfolio.
Classifications
industries
No industries detected
applications
ERP & Process Management
AskAI Classifications
Labels
Bioinformatics Software
Life Sciences Software
SaaS
Linked Companies
QIAGEN
$1B+